PPAR agonists: multimodal drugs for the treatment of type-2 diabetes

This publication has 100 references indexed in Scilit:

• Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice
  Atherosclerosis, 2007
• Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones
  Journal of Clinical Investigation, 2007
• Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
  Nature, 2007
• Selective Modulators of PPAR-γActivity: Molecular Aspects Related to Obesity and Side-Effects
  PPAR Research, 2007
• Combined Use of Rosiglitazone and Fenofibrate in Patients With Type 2 Diabetes
  Diabetes, 2007
• A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
  Nature, 2005
• Regulation of Muscle Fiber Type and Running Endurance by PPARδ
  PLOS Biology, 2004
• Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor α
  Biochemical and Biophysical Research Communications, 2001
• Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
  Journal of Clinical Investigation, 1999
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987